In addition to its lectin pathway inhibitors, the company is advancing its development of antibodies and small-molecule inhibitors against MASP-3 to block activation of the alternative pathway.

Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patien ...

Mannose-binding lectin (MBL) is a critical serum protein of the innate immune system that recognises distinct carbohydrate signatures on pathogens, initiating the lectin pathway of the complement ...

Omeros is a first-in-class monoclonal antibody that inhibits the lectin pathway of complement in hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).